The introduction of the fusion inhibitors in the HAART-regimens

H. Hasson, A. Castagna, M. Clementi, S. Menzo, A. Danise, A. Lazzarin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Interference with HIV entry into target cells provides a novel approach to the treatment of HIV infection. The inhibition of virus fusion with the co-receptor substrate seems the most specific and potentially best way to interfere with HIV infection and replication. The efficacy of the first compound available (enfuvirtide) is evident after the pre-registrative phase II and III studies showing also that the presence of anti gp 41 antibodies in the plasma of the treated patients does not interfere with drug activity. In the failing enfuvirtide treated patients resistant virus was detected in 7/7 after > one year of treatment with genotypic mutations in the HR env domain, however no interclass cross resistance was evidenced. Mutants selected in vivo demonstrated a slight reduction of replication capacity.

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalNew Microbiologica
Volume27
Issue number2 SUPPL. 1
Publication statusPublished - 2004

Fingerprint

Highly Active Antiretroviral Therapy
HIV Infections
Viruses
HIV
Mutation
Antibodies
Therapeutics
Pharmaceutical Preparations
enfuvirtide

Keywords

  • Enfuvirtide
  • Fusion inhibitors
  • HAART
  • HIV resistance

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Hasson, H., Castagna, A., Clementi, M., Menzo, S., Danise, A., & Lazzarin, A. (2004). The introduction of the fusion inhibitors in the HAART-regimens. New Microbiologica, 27(2 SUPPL. 1), 11-16.

The introduction of the fusion inhibitors in the HAART-regimens. / Hasson, H.; Castagna, A.; Clementi, M.; Menzo, S.; Danise, A.; Lazzarin, A.

In: New Microbiologica, Vol. 27, No. 2 SUPPL. 1, 2004, p. 11-16.

Research output: Contribution to journalArticle

Hasson, H, Castagna, A, Clementi, M, Menzo, S, Danise, A & Lazzarin, A 2004, 'The introduction of the fusion inhibitors in the HAART-regimens', New Microbiologica, vol. 27, no. 2 SUPPL. 1, pp. 11-16.
Hasson H, Castagna A, Clementi M, Menzo S, Danise A, Lazzarin A. The introduction of the fusion inhibitors in the HAART-regimens. New Microbiologica. 2004;27(2 SUPPL. 1):11-16.
Hasson, H. ; Castagna, A. ; Clementi, M. ; Menzo, S. ; Danise, A. ; Lazzarin, A. / The introduction of the fusion inhibitors in the HAART-regimens. In: New Microbiologica. 2004 ; Vol. 27, No. 2 SUPPL. 1. pp. 11-16.
@article{a09b691723a54039ae8d638c74d195e2,
title = "The introduction of the fusion inhibitors in the HAART-regimens",
abstract = "Interference with HIV entry into target cells provides a novel approach to the treatment of HIV infection. The inhibition of virus fusion with the co-receptor substrate seems the most specific and potentially best way to interfere with HIV infection and replication. The efficacy of the first compound available (enfuvirtide) is evident after the pre-registrative phase II and III studies showing also that the presence of anti gp 41 antibodies in the plasma of the treated patients does not interfere with drug activity. In the failing enfuvirtide treated patients resistant virus was detected in 7/7 after > one year of treatment with genotypic mutations in the HR env domain, however no interclass cross resistance was evidenced. Mutants selected in vivo demonstrated a slight reduction of replication capacity.",
keywords = "Enfuvirtide, Fusion inhibitors, HAART, HIV resistance",
author = "H. Hasson and A. Castagna and M. Clementi and S. Menzo and A. Danise and A. Lazzarin",
year = "2004",
language = "English",
volume = "27",
pages = "11--16",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - The introduction of the fusion inhibitors in the HAART-regimens

AU - Hasson, H.

AU - Castagna, A.

AU - Clementi, M.

AU - Menzo, S.

AU - Danise, A.

AU - Lazzarin, A.

PY - 2004

Y1 - 2004

N2 - Interference with HIV entry into target cells provides a novel approach to the treatment of HIV infection. The inhibition of virus fusion with the co-receptor substrate seems the most specific and potentially best way to interfere with HIV infection and replication. The efficacy of the first compound available (enfuvirtide) is evident after the pre-registrative phase II and III studies showing also that the presence of anti gp 41 antibodies in the plasma of the treated patients does not interfere with drug activity. In the failing enfuvirtide treated patients resistant virus was detected in 7/7 after > one year of treatment with genotypic mutations in the HR env domain, however no interclass cross resistance was evidenced. Mutants selected in vivo demonstrated a slight reduction of replication capacity.

AB - Interference with HIV entry into target cells provides a novel approach to the treatment of HIV infection. The inhibition of virus fusion with the co-receptor substrate seems the most specific and potentially best way to interfere with HIV infection and replication. The efficacy of the first compound available (enfuvirtide) is evident after the pre-registrative phase II and III studies showing also that the presence of anti gp 41 antibodies in the plasma of the treated patients does not interfere with drug activity. In the failing enfuvirtide treated patients resistant virus was detected in 7/7 after > one year of treatment with genotypic mutations in the HR env domain, however no interclass cross resistance was evidenced. Mutants selected in vivo demonstrated a slight reduction of replication capacity.

KW - Enfuvirtide

KW - Fusion inhibitors

KW - HAART

KW - HIV resistance

UR - http://www.scopus.com/inward/record.url?scp=11844275297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844275297&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 11

EP - 16

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 2 SUPPL. 1

ER -